[go: up one dir, main page]

ES2054256T3 - Fragmentos de peptido de hiv. - Google Patents

Fragmentos de peptido de hiv.

Info

Publication number
ES2054256T3
ES2054256T3 ES90308662T ES90308662T ES2054256T3 ES 2054256 T3 ES2054256 T3 ES 2054256T3 ES 90308662 T ES90308662 T ES 90308662T ES 90308662 T ES90308662 T ES 90308662T ES 2054256 T3 ES2054256 T3 ES 2054256T3
Authority
ES
Spain
Prior art keywords
proline
peptide fragments
hiv peptide
thyrine
isoleucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90308662T
Other languages
English (en)
Inventor
Andrew James Mcmichael
Douglas Fraser Nixon
Alain Robert Michael Townsend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biomedical Inc
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43806939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2054256(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Application granted granted Critical
Publication of ES2054256T3 publication Critical patent/ES2054256T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DESCRIBE UN PEPTIDO QUE TIENEN LA SECUENCIA DE AMINOACIDOS DE UN FRAGMENTO DE HIV, LA CUAL INTERACTUA ESPECIFICAMENTE CON UN ANTIGENO PARTICULAR DE UN LEUCOCITO HUMANO (HLA), MOLECULA DE CLASE (I, PARA ESTIMULAR LA INMUNIDAD CITOTOXICA DEL T LINFOCITO. TAL FRAGMENTO PUEDE UTILIZARSE EN UNA VACUNA POTENCIAL CONTRA EL SIDA, Y PARA EL DIAGNOSTICO Y TERAPIA. EL PEPTIDO TIENE LA SECUENCIA: NH2-ASPARAGINA-PROLINA-PROLINA-ISOLEUCENINA-PROLINA-VALINA-GLICINA-GLUTAMATO-I SOLEUCINA-TIROSINA-LISINA-ARGIMINA-TRIPTOFAM-ISOLEUCINA-ISOLEUCINA-(CISTEINA)X -COOS, DONDE X ES 0 O 1.
ES90308662T 1989-08-09 1990-08-07 Fragmentos de peptido de hiv. Expired - Lifetime ES2054256T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898918200A GB8918200D0 (en) 1989-08-09 1989-08-09 The peptide fragments of hiv

Publications (1)

Publication Number Publication Date
ES2054256T3 true ES2054256T3 (es) 1994-08-01

Family

ID=43806939

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90308662T Expired - Lifetime ES2054256T3 (es) 1989-08-09 1990-08-07 Fragmentos de peptido de hiv.

Country Status (12)

Country Link
US (1) US5700635A (es)
EP (1) EP0412766B1 (es)
JP (1) JPH04507100A (es)
AT (1) ATE103294T1 (es)
CA (1) CA2064691A1 (es)
DE (1) DE69007571T2 (es)
DK (1) DK0412766T3 (es)
ES (1) ES2054256T3 (es)
GB (2) GB8918200D0 (es)
HK (1) HK141494A (es)
SG (1) SG130094G (es)
WO (1) WO1991001996A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
DE68925660T2 (de) * 1988-06-10 1996-09-26 United Biomedical Inc Peptidfragmente von HIV
CA2072351A1 (en) * 1990-01-05 1991-07-06 Andrew J. Mcmichael Hiv-1 core protein fragments
US5603933A (en) * 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
CA2173138A1 (en) * 1993-10-19 1995-04-27 Masafumi Takiguchi Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
GB9426153D0 (en) * 1994-12-23 1995-02-22 Medical Res Council Improvements in or relating to vaccines
BR0016510A (pt) * 1999-12-23 2002-08-27 Medical Res Council Aperfeçoamentos em ou relacionados as respostas imunes ao hiv
CU23235A1 (es) * 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
EP2352137A3 (en) * 2008-04-24 2014-01-15 Avery Dennison Corporation Sheet having removable labels and related method
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3687A (da) * 1986-01-06 1987-07-07 Hoffmann La Roche Polypeptider og fremgangsmaade til fremstilling deraf
NO881151L (no) * 1987-03-27 1988-09-28 Syntello Ab Syntetisk hiv-1-antigen.
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection

Also Published As

Publication number Publication date
WO1991001996A1 (en) 1991-02-21
DK0412766T3 (da) 1994-07-18
JPH04507100A (ja) 1992-12-10
EP0412766A1 (en) 1991-02-13
ATE103294T1 (de) 1994-04-15
CA2064691A1 (en) 1991-02-10
US5700635A (en) 1997-12-23
GB2250994B (en) 1993-08-25
DE69007571D1 (de) 1994-04-28
GB8918200D0 (en) 1989-09-20
GB2250994A (en) 1992-06-24
GB9201468D0 (en) 1992-04-01
HK141494A (en) 1994-12-23
EP0412766B1 (en) 1994-03-23
SG130094G (en) 1995-01-13
DE69007571T2 (de) 1994-09-08

Similar Documents

Publication Publication Date Title
ES2054256T3 (es) Fragmentos de peptido de hiv.
GB2255093A (en) Hiv-1 core protein fragments
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
CO4890856A1 (es) CICATRIZACION DE FRACTURAS USANDO ANALOGOS DE PTHrP
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
BR9106374A (pt) Vacina oral e processo de extrair uma imunoresponsta em um mamifero
ES2176284T3 (es) Amidas de peptidos inhibidoras del cancer de seres humanos.
ES2081102T3 (es) Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
ES2054353T3 (es) Expresion de las alipoproteinas humanas ai-milano en levadura.
DE68925660D1 (de) Peptidfragmente von HIV
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ES2146214T3 (es) Vacunas para actinobacillus pleuropneumoniae.
NL300189I1 (nl) Acellulair vaccin.
AR247404A1 (es) Composicion peptidica de uso exclusivo para el diagnostico de la enfermedad de la malaria y procedimiento de sintesis de dicha composicion peptidica
ES2059305T3 (es) Proteina del virus de la seudorrabia.
ES2191206T3 (es) Nueva utilizacion de la creatina.
BR9612422A (pt) Pseudo-partìculas virais recombinantes, composição, utilização de pseudo-partìculas, e, processo de estimulação in vitro de respostas t citotóxicas de linfócitos provenientes de indivìduos atingidos por infecções virais ou tumorais.
DK1694271T3 (da) FSH-glykosyleringsmutant
ES2085199B1 (es) Un procedimiento para la preparacion de una formulacion depot.
AR010568A1 (es) Polipeptido, composicion de vacuna, uso del polipeptido en la fabricacion de una composicion, y metodo para producir en un mamifero una respuestainmuno-protectora contra la infeccion de helicobacter pylori
ATE210989T1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
ES2158857T3 (es) Vacunas a base de estreptoquinasa.
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
YU64192A (sh) Analozi insulina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 412766

Country of ref document: ES